NPI 1225492788: Open Payments
NPI 1225492788. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$151 in 7 payments from 6 companies in 2025. Trend: 2023 $148 · 2024 $144 · 2025 $151
Food & beverage: $151
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 2 | $46 |
| AKEBIA THERAPEUTICS INC | 1 | $24 |
| Ardelyx, Inc. | 1 | $24 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: VELPHORO, Vafseo, IBSRELA, FARXIGA, JARDIANCE, JYNARQUE.
